In a report released today, Craig Bijou from Cantor Fitzgerald maintained a Buy rating on Cerus Corp (CERS), with a price target of $9. The company’s shares opened today at $5.35.
Bijou said:
“We rate CERS Overweight and have a 12-month price target of $9. CERS commercializes INTERCEPT, the only FDA-approved system for pathogen- inactivated (PI) blood components. We believe 2019 will be a pivotal year for the company as it continues to penetrate the platelet transfusion market in key geographical regions (US and internationally), which we expect to drive double-digit revenue growth longer term. CERS is seeking regulatory approval in Europe and the US to use its INTERCEPT system to treat red cells, a company-estimated $5B market.”
According to TipRanks.com, Bijou is a 3-star analyst with an average return of 1.6% and a 36.8% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Ra Medical Systems Inc, and Integra Lifesciences.
Currently, the analyst consensus on Cerus Corp is a Moderate Buy with an average price target of $8.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.05 and a one-year low of $3.35. Currently, Cerus Corp has an average volume of 865.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products. It produces blood system for platelets and plasma. It markets its products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
